Trade Ovid Therapeutics Inc. - OVID CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Ovid Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 2.94 |
| Open* | 2.85 |
| 1-Year Change* | 64.74% |
| Day's Range* | 2.85 - 3.17 |
| 52 wk Range | 1.62-4.14 |
| Average Volume (10 days) | 102.07K |
| Average Volume (3 months) | 2.65M |
| Market Cap | 231.83M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 70.68M |
| Revenue | 296.41K |
| EPS | -0.69 |
| Dividend (Yield %) | N/A |
| Beta | 1.00 |
| Next Earnings Date | Mar 11, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 3.16 | 0.33 | 11.66% | 2.83 | 3.18 | 2.83 |
| Nov 30, 2023 | 2.94 | 0.26 | 9.70% | 2.68 | 3.04 | 2.68 |
| Nov 29, 2023 | 3.01 | 0.03 | 1.01% | 2.98 | 3.08 | 2.87 |
| Nov 28, 2023 | 3.02 | -0.18 | -5.63% | 3.20 | 3.20 | 2.99 |
| Nov 27, 2023 | 3.22 | 0.00 | 0.00% | 3.22 | 3.31 | 3.20 |
| Nov 24, 2023 | 3.21 | -0.08 | -2.43% | 3.29 | 3.41 | 3.21 |
| Nov 22, 2023 | 3.31 | 0.12 | 3.76% | 3.19 | 3.37 | 3.19 |
| Nov 21, 2023 | 3.27 | 0.03 | 0.93% | 3.24 | 3.32 | 3.24 |
| Nov 20, 2023 | 3.28 | 0.07 | 2.18% | 3.21 | 3.29 | 3.21 |
| Nov 17, 2023 | 3.23 | 0.05 | 1.57% | 3.18 | 3.27 | 3.18 |
| Nov 16, 2023 | 3.25 | -0.03 | -0.91% | 3.28 | 3.31 | 3.18 |
| Nov 15, 2023 | 3.34 | -0.04 | -1.18% | 3.38 | 3.48 | 3.30 |
| Nov 14, 2023 | 3.49 | 0.19 | 5.76% | 3.30 | 3.52 | 3.29 |
| Nov 13, 2023 | 3.28 | 0.10 | 3.14% | 3.18 | 3.33 | 3.18 |
| Nov 10, 2023 | 3.23 | 0.13 | 4.19% | 3.10 | 3.27 | 3.10 |
| Nov 9, 2023 | 3.14 | -0.13 | -3.98% | 3.27 | 3.32 | 3.07 |
| Nov 8, 2023 | 3.33 | 0.05 | 1.52% | 3.28 | 3.45 | 3.26 |
| Nov 7, 2023 | 3.31 | 0.06 | 1.85% | 3.25 | 3.37 | 3.16 |
| Nov 6, 2023 | 3.24 | -0.32 | -8.99% | 3.56 | 3.56 | 3.20 |
| Nov 3, 2023 | 3.54 | 0.10 | 2.91% | 3.44 | 3.65 | 3.44 |
Ovid Therapeutics Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, March 11, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 Ovid Therapeutics Inc Earnings Release Q4 2023 Ovid Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 1.50275 | 208.383 | 12.6172 | 0 | 0 |
| Revenue | 1.50275 | 208.383 | 12.6172 | 0 | 0 |
| Total Operating Expense | 57.0509 | 84.1737 | 94.0482 | 61.4095 | 52.9317 |
| Selling/General/Admin. Expenses, Total | 32.4325 | 37.2341 | 30.6308 | 19.2518 | 19.1416 |
| Research & Development | 24.6184 | 46.9396 | 63.4174 | 42.1576 | 33.79 |
| Operating Income | -55.5482 | 124.209 | -81.431 | -61.4095 | -52.9317 |
| Interest Income (Expense), Net Non-Operating | 1.87913 | -0.04569 | 0.3954 | 0.94822 | 0.95207 |
| Net Income Before Taxes | -54.169 | 124.163 | -81.0356 | -60.4612 | -51.9796 |
| Net Income After Taxes | -54.169 | 122.835 | -81.0356 | -60.4612 | -51.9796 |
| Net Income Before Extra. Items | -54.169 | 122.835 | -81.0356 | -60.4612 | -51.9796 |
| Net Income | -54.169 | 122.835 | -81.0356 | -60.4612 | -51.9796 |
| Income Available to Common Excl. Extra. Items | -54.169 | 119.839 | -81.0356 | -60.4612 | -51.9796 |
| Income Available to Common Incl. Extra. Items | -54.169 | 119.839 | -81.0356 | -60.4612 | -51.9796 |
| Dilution Adjustment | |||||
| Diluted Net Income | -54.169 | 119.839 | -81.0356 | -60.4612 | -51.9796 |
| Diluted Weighted Average Shares | 70.4248 | 68.068 | 58.4513 | 39.2172 | 24.631 |
| Diluted EPS Excluding Extraordinary Items | -0.76918 | 1.76058 | -1.38638 | -1.5417 | -2.11033 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.76918 | 1.76058 | -1.38638 | -1.5417 | -2.11033 |
| Total Extraordinary Items | |||||
| Total Adjustments to Net Income | -2.99532 | ||||
| Other, Net | -0.5 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.075 | 0.06616 | 0.04628 | 0.0111 | 0 |
| Revenue | 0.075 | 0.06616 | 0.04628 | 0.0111 | 0 |
| Total Operating Expense | 14.247 | 14.9585 | 12.2192 | 12.815 | 14.3043 |
| Selling/General/Admin. Expenses, Total | 8.24822 | 8.34375 | 6.66299 | 7.63171 | 8.25762 |
| Research & Development | 5.99877 | 6.61472 | 5.55621 | 5.18325 | 6.04667 |
| Operating Income | -14.172 | -14.8923 | -12.1729 | -12.8039 | -14.3043 |
| Interest Income (Expense), Net Non-Operating | 1.36365 | 1.1361 | 1.06812 | 1.03609 | 0.31587 |
| Net Income Before Taxes | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Net Income After Taxes | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Net Income Before Extra. Items | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Net Income | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Income Available to Common Incl. Extra. Items | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Diluted Net Income | -12.4083 | -13.3562 | -11.5048 | -11.9678 | -14.5884 |
| Diluted Weighted Average Shares | 70.5342 | 70.4907 | 70.4733 | 70.4305 | 70.3915 |
| Diluted EPS Excluding Extraordinary Items | -0.17592 | -0.18947 | -0.16325 | -0.16992 | -0.20725 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.17592 | -0.18947 | -0.16325 | -0.16992 | -0.20725 |
| Other Operating Expenses, Total | |||||
| Other, Net | 0.4 | 0.4 | -0.4 | -0.2 | -0.6 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 131.381 | 190.479 | 74.8432 | 79.8132 | 44.2682 |
| Cash and Short Term Investments | 129.001 | 187.798 | 72.0339 | 76.7391 | 41.5006 |
| Cash & Equivalents | 42.0148 | 187.592 | 70.0566 | 41.3956 | 35.5623 |
| Total Receivables, Net | 0 | 0.14176 | 1.13115 | ||
| Prepaid Expenses | 2.37928 | 2.6816 | 2.66751 | 1.94293 | 2.7675 |
| Other Current Assets, Total | |||||
| Total Assets | 155.266 | 194.545 | 75.9255 | 80.8437 | 47.6496 |
| Property/Plant/Equipment, Total - Net | 16.0706 | 0.24276 | 0.13562 | 0.06836 | 0.06987 |
| Property/Plant/Equipment, Total - Gross | 1.42303 | 0.50497 | 0.32096 | 0.19372 | 0.15603 |
| Accumulated Depreciation, Total | -0.58138 | -0.26221 | -0.18534 | -0.12535 | -0.08616 |
| Other Long Term Assets, Total | 1.96984 | 2.02688 | 0.6278 | 0.96218 | 3.31159 |
| Total Current Liabilities | 6.99153 | 14.7983 | 22.0628 | 10.5336 | 8.84446 |
| Accounts Payable | 1.95291 | 7.12705 | 5.44621 | 3.2561 | 3.7556 |
| Accrued Expenses | 5.03862 | 7.67128 | 12.0327 | 7.26671 | 5.08886 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 4.58388 | 0.0108 | ||
| Total Liabilities | 22.9932 | 14.7983 | 32.2939 | 10.8202 | 8.84446 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 16.0017 | 0 | 10.2311 | 0.28656 | |
| Total Equity | 132.273 | 179.746 | 43.6317 | 70.0236 | 38.8051 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00001 | 0 |
| Common Stock | 0.07047 | 0.07036 | 0.06574 | 0.05471 | 0.02465 |
| Additional Paid-In Capital | 357.771 | 351.034 | 337.758 | 283.123 | 191.478 |
| Retained Earnings (Accumulated Deficit) | -225.527 | -171.358 | -294.192 | -213.157 | -152.695 |
| Total Liabilities & Shareholders’ Equity | 155.266 | 194.545 | 75.9255 | 80.8437 | 47.6496 |
| Total Common Shares Outstanding | 70.4669 | 70.3649 | 65.7432 | 54.7103 | 24.6541 |
| Total Preferred Shares Outstanding | 0.00125 | 0.00125 | 0.00325 | 0.00776 | 0 |
| Cash | 2.85304 | 0.20556 | 1.97732 | 0.50154 | 0.92735 |
| Short Term Investments | 84.1336 | 0 | 34.842 | 5.01103 | |
| Other Equity, Total | -0.04219 | 0 | 0.00247 | -0.00183 | |
| Accounts Receivable - Trade, Net | 0 | 0.14176 | 1.13115 | ||
| Intangibles, Net | 0.2221 | 0.164 | 0.3189 | ||
| Long Term Investments | 5.62255 | 1.63199 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 91.7134 | 102.171 | 119.519 | 131.381 | 140.498 |
| Cash and Short Term Investments | 87.0717 | 96.5174 | 117.72 | 129.001 | 137.858 |
| Cash | 0.80918 | 0.8686 | 2.34636 | 2.85304 | 1.74906 |
| Cash & Equivalents | 56.6274 | 70.7547 | 60.7056 | 42.0148 | 56.5081 |
| Total Receivables, Net | |||||
| Accounts Receivable - Trade, Net | |||||
| Prepaid Expenses | 4.64167 | 5.65347 | 1.79934 | 2.37928 | 2.64048 |
| Total Assets | 125.029 | 136.23 | 143.367 | 155.266 | 165.032 |
| Property/Plant/Equipment, Total - Net | 15.0117 | 15.3676 | 15.7224 | 16.0706 | 16.3373 |
| Property/Plant/Equipment, Total - Gross | 1.44963 | 1.44439 | 1.43659 | 1.42303 | 1.30309 |
| Accumulated Depreciation, Total | -0.89946 | -0.79513 | -0.68984 | -0.58138 | -0.44975 |
| Intangibles, Net | 0.22205 | 0.26337 | 0.18591 | 0.2221 | 0.27545 |
| Other Long Term Assets, Total | 1.95735 | 1.95735 | 1.95685 | 1.96984 | 1.96934 |
| Total Current Liabilities | 8.66346 | 10.1415 | 6.721 | 6.99153 | 6.7323 |
| Accounts Payable | 1.21656 | 3.76329 | 1.83149 | 1.95291 | 1.03307 |
| Accrued Expenses | 7.44689 | 6.37823 | 4.88951 | 5.03862 | 5.4147 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.28454 | ||||
| Total Liabilities | 23.7367 | 25.5311 | 22.4193 | 22.9932 | 22.9811 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 15.0733 | 15.3896 | 15.6983 | 16.0017 | 16.2488 |
| Total Equity | 101.292 | 110.699 | 120.948 | 132.273 | 142.051 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.07068 | 0.0706 | 0.07049 | 0.07047 | 0.07047 |
| Additional Paid-In Capital | 363.769 | 361.914 | 359.754 | 357.771 | 356.085 |
| Retained Earnings (Accumulated Deficit) | -262.543 | -251.291 | -238.883 | -225.527 | -214.022 |
| Other Equity, Total | -0.00388 | 0.00521 | 0.00563 | -0.04219 | -0.08279 |
| Total Liabilities & Shareholders’ Equity | 125.029 | 136.23 | 143.367 | 155.266 | 165.032 |
| Total Common Shares Outstanding | 70.6805 | 70.6028 | 70.4915 | 70.4669 | 70.4669 |
| Total Preferred Shares Outstanding | 0.00125 | 0.00125 | 0.00125 | 0.00125 | 0.00125 |
| Long Term Investments | 16.1242 | 16.4705 | 5.98245 | 5.62255 | 5.95164 |
| Short Term Investments | 29.6351 | 24.8941 | 54.6681 | 84.1336 | 79.6005 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -54.169 | 122.835 | -81.0356 | -60.4612 | -51.9796 |
| Cash From Operating Activities | -55.2271 | 118.612 | -51.5839 | -51.0906 | -45.5585 |
| Cash From Operating Activities | 0.51251 | 0.23708 | 0.30685 | 0.255 | 0.14173 |
| Non-Cash Items | 6.66085 | 12.3545 | 7.52535 | 5.20579 | 7.06855 |
| Changes in Working Capital | -8.23145 | -16.8144 | 21.6195 | 3.90983 | -0.78915 |
| Cash From Investing Activities | -87.8832 | -1.8214 | 34.6482 | -30.041 | -5.36364 |
| Capital Expenditures | -1.41878 | -0.18941 | -0.39068 | -0.24405 | -0.35202 |
| Cash From Financing Activities | 0.18066 | 0.90408 | 47.0725 | 86.5392 | 0.28614 |
| Financing Cash Flow Items | 0 | -0.02131 | -0.16325 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.18066 | 0.9254 | 47.2357 | 86.5392 | 0.28614 |
| Net Change in Cash | -142.93 | 117.694 | 30.1368 | 5.40753 | -50.636 |
| Other Investing Cash Flow Items, Total | -86.4644 | -1.63199 | 35.0389 | -29.797 | -5.01162 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.3562 | -54.169 | -42.6642 | -30.6965 | -16.1081 |
| Cash From Operating Activities | -12.1123 | -55.2271 | -46.0514 | -33.375 | -20.0864 |
| Cash From Operating Activities | 0.14465 | 0.51251 | 0.32753 | 0.17211 | 0.07381 |
| Non-Cash Items | 1.3693 | 6.66085 | 4.45062 | 2.94724 | 0.26067 |
| Changes in Working Capital | -0.27 | -8.23145 | -8.1653 | -5.79789 | -4.31284 |
| Cash From Investing Activities | 30.2288 | -87.8832 | -83.7137 | -81.7534 | -1.07617 |
| Capital Expenditures | -0.01356 | -1.41878 | -1.35578 | -1.33718 | -0.07617 |
| Other Investing Cash Flow Items, Total | 30.2424 | -86.4644 | -82.3579 | -80.4162 | -1 |
| Cash From Financing Activities | 0.06699 | 0.18066 | 0.22426 | 0.14263 | 0.03308 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.06699 | 0.18066 | 0.22426 | 0.14263 | 0.03308 |
| Net Change in Cash | 18.1836 | -142.93 | -129.541 | -114.986 | -21.1295 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | Corporation | 10.6681 | 7531996 | 1250000 | 2022-07-01 | LOW |
| BVF Partners L.P. | Hedge Fund | 9.7037 | 6851051 | 0 | 2023-06-30 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 8.6645 | 6117400 | 0 | 2023-06-30 | LOW |
| Rubric Capital Management LP | Hedge Fund | 7.7134 | 5445910 | -1555214 | 2023-06-30 | MED |
| Levin (Jeremy M) | Individual Investor | 6.7589 | 4771990 | 0 | 2023-04-13 | |
| Madison Avenue Partners LP | Hedge Fund | 5.1118 | 3609054 | 301449 | 2023-07-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3949 | 3102915 | 2387583 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1064 | 2899228 | 288626 | 2023-06-30 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 3.5409 | 2500000 | 0 | 2023-06-30 | MED |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.5222 | 1780730 | -143 | 2023-06-30 | MED |
| TLS Advisors LLC | Investment Advisor | 2.1112 | 1490534 | 1490534 | 2022-12-31 | |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7182 | 1213085 | 713450 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.4541 | 1026631 | 834898 | 2023-06-30 | LOW |
| Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 1.2249 | 864822 | 0 | 2023-06-30 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 1.1347 | 801152 | -26428 | 2023-06-30 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6187 | 436827 | 329621 | 2023-06-30 | LOW |
| Wells Fargo Advisors | Research Firm | 0.6066 | 428247 | -2000 | 2023-06-30 | LOW |
| ARIAD Asset Management GmbH | Investment Advisor | 0.4881 | 344634 | 0 | 2023-07-31 | MED |
| BlackRock Investment Management, LLC | Investment Advisor/Hedge Fund | 0.239 | 168763 | 159087 | 2023-06-30 | LOW |
| BNY Mellon Asset Management | Investment Advisor | 0.2346 | 165659 | 442 | 2023-09-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ovid Therapeutics Inc. Company profile
About Ovid Therapeutics Inc
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early-stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of dravet syndrome and lennox-gastaut syndrome. OV329, which is under late-stage program, is focused on treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV882, which is under early-stage program, is for the treatment of angelman syndrome and is being developed in collaboration with the University of Connecticut School of Medicine. OV815 is for the treatment of KIF1A Associated Neurological Disorder (KAND) and is being developed in collaboration with Columbia University Irving Medical Center.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ovid Therapeutics Inc revenues increased from $12.6M to $208.4M. Net income applicable to common stockholders totaled $119.8M vs. loss of $81M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development- Balancing decrease of 25% to $45.2M (expense).
| Industry: | Bio Therapeutic Drugs |
441 Ninth Avenue, 14Th Floor
NEW YORK
NEW YORK 10001
US
Income Statement
- Annual
- Quarterly
News
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com